4.6 Article

Breast-conserving therapy is associated with better survival than mastectomy in Early-stage breast cancer: A propensity score analysis

期刊

CANCER MEDICINE
卷 11, 期 7, 页码 1646-1658

出版社

WILEY
DOI: 10.1002/cam4.4510

关键词

breast-conserving therapy; mastectomy; survival; tumor subtypes

类别

资金

  1. Natural Science Foundation of Jiangsu Province [BK20191208]
  2. Nantong Health Committee [MA2020009]
  3. Nantong Science and Technology Foundation [JCZ20204]

向作者/读者索取更多资源

This study compared the efficacy of breast-conserving therapy (BCT) and mastectomy in early-stage breast cancer patients using the SEER database. The results showed that BCT was associated with improved overall survival (OS) and breast cancer-specific survival (BCSS) compared to mastectomy. Patients with different subtypes and age groups also showed better survival outcomes with BCT compared to mastectomy.
Background Recent retrospective studies have reported that breast-conserving therapy (BCT) led to improved overall survival (OS) than mastectomy in some populations. We aimed to compare the efficacy of BCT and mastectomy using the SEER database. Materials and methods Between 2010 and 2015, 99,790 eligible patients were identified. We included early-stage breast cancer patients with 5cm or smaller tumors and three or fewer positive lymph nodes in our study. We compared the OS and breast cancer-specific survival (BCSS) results among patients with BCT and those with mastectomy. Kaplan-Meier plots, Cox proportional hazard regressions, competing risk analysis, and multivariate regressions were used to evaluate the outcomes. Propensity-score matching was used to assemble a cohort of patients with similar baseline characteristics. Results In our study, 77,452 (77.6%) patients underwent BCT and 22,338 (22.4%) underwent mastectomy. The 5-year OS rate was 94.7% in the BCT group and 87.6% in the mastectomy group, and the 5-year BCSS was 97.2% in the BCT and 94.3% in the mastectomy group. Multivariate analysis in the matched cohort showed that women underwent mastectomy was associated with worse OS (Hazard ratio (HR) = 1.79; 95% confidence intervals (CIs) = 1.59-2.02, p < 0.001) and BCSS (HR = 1.88; 95% CIs = 1.61-2.18, p < 0.001) results compared with those underwent BCT. Patients with different subtypes and age group (>50 years old; <= 50 years old) received BCT showed significantly better OS and BCSS results than those received mastectomy. The effect of surgery choice on survival yielded similar results either for all patients or matched cohorts. Conclusions Our study showed that BCT was associated with improved survival compared with mastectomy in early-stage breast cancer patients. It seems advisable to encourage patients to receive BCT rather than mastectomy in early-stage patients when feasible and appropriate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+breast cancer

X. He, F. J. Esteva, J. Ensor, G. N. Hortobagyi, M. -H. Lee, S. -C. J. Yeung

ANNALS OF ONCOLOGY (2012)

Article Oncology

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients

X. -X. He, S. M. Tu, M. -H. Lee, S. -C. J. Yeung

ANNALS OF ONCOLOGY (2011)

Article Pharmacology & Pharmacy

A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours

Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan, Tongyu Lin

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)

Article Oncology

Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis

Xuexin He, Jiali Ji, Rongrong Dong, Hong Liu, Xiaolan Dai, Chongjian Wang, Francisco J. Esteva, Sai-Ching Jim Yeung

BREAST CANCER RESEARCH AND TREATMENT (2019)

Article Oncology

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

Xuexin He, Jiali Ji, Mei Tian, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching Jim Yeung

CLINICAL CANCER RESEARCH (2019)

Review Radiology, Nuclear Medicine & Medical Imaging

Transpathology: molecular imaging-based pathology

Mei Tian, Xuexin He, Chentao Jin, Xiao He, Shuang Wu, Rui Zhou, Xiaohui Zhang, Kai Zhang, Weizhong Gu, Jing Wang, Hong Zhang

Summary: Pathology is a medical specialty focused on studying the nature and causes of disease, and plays a crucial role in connecting basic research and clinical medicine. Challenges such as invasiveness and sample representativeness limitations exist in traditional pathology, while molecular imaging provides a noninvasive way to visualize and measure biological processes at the molecular level. A new pathophysiology visualization system based on molecular imaging is showing great potential in reforming pathological practice, driving improvements in trans-scale imaging, transparency, and translation processes.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

Article Oncology

Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors

Xuexin He, Jiali Ji, Xiaolan Dai, Aiham Z. Qdaisat, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching J. Yeung

Summary: This study reviewed early HER2-positive breast cancer patients at the institution from 1998 to 2009 and found that hypertension and history of coronary artery disease were independent prognostic factors for late severe CV events. Combining anthracycline and anti-HER2 therapy regimens was beneficial for improving overall survival.

CLINICAL CANCER RESEARCH (2021)

Article Oncology

Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients

Xuexin He, Xiaolan Dai, Jiali Ji, Hong Liu, Ganggang Shi, Sai-Ching Jim Yeung

Summary: This study compared the efficacy and cardiac toxicity of different neoadjuvant chemotherapy regimens in HER2+ breast cancer patients. The results showed that the PH-FECH regimen had higher progression-free survival and pathologic complete response rates compared to the TCH regimen, but it was associated with a higher risk of cardiac toxicity.

CLINICAL BREAST CANCER (2022)

Article Radiology, Nuclear Medicine & Medical Imaging

A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT

Xiaohui Zhang, Lin Chen, Han Jiang, Xuexin He, Liu Feng, Miaoqi Ni, Mindi Ma, Jing Wang, Teng Zhang, Shuang Wu, Rui Zhou, Chentao Jin, Kai Zhang, Wenbin Qian, Zexin Chen, Cheng Zhuo, Hong Zhang, Mei Tian

Summary: The hybrid nomograms combining RS with IPI significantly improved survival prediction in DLBCL. Radiomic analysis on MBV may serve as a potential approach for prognosis assessment in DLBCL.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Article Immunology

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer

Qing Zhao, Xuexin He, Xiyi Qin, Yu Liu, Han Jiang, Jing Wang, Shuang Wu, Rui Zhou, Congcong Yu, Suling Liu, Hong Zhang, Mei Tian

Summary: This study explores a novel combination therapy for TNBC using Losartan and Dox-L in combination with alpha-PD1, demonstrating that it can optimize the efficacy by reducing the stroma and enhancing immune stimulation, which improves the immunosuppressive microenvironment and enhances anti-tumor immunity.

FRONTIERS IN IMMUNOLOGY (2022)

暂无数据